Cargando…

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism

This article describes the population pharmacokinetics (PK) of dalteparin in pediatric patients with venous thromboembolism (VTE). A prospective multicenter open‐label study was conducted in children who required anticoagulation for the treatment of VTE. The study population included children with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damle, Bharat, Jen, Frank, Sherman, Nancy, Jani, Darshana, Sweeney, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Pediatric Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818112/ https://www.ncbi.nlm.nih.gov/pubmed/32827160 http://dx.doi.org/10.1002/jcph.1716

Ejemplares similares

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Editorial: Pediatric Venous Thromboembolism
por: Branchford, Brian R., et al.
Publicado: (2018)

The Impact of Central Venous Catheters on Pediatric Venous Thromboembolism
por: Jaffray, Julie, et al.
Publicado: (2017)

Treatment of Venous Thromboembolism in Pediatric Patients
por: Malec, Lynn, et al.
Publicado: (2017)

Pediatric Hospital Acquired Venous Thromboembolism
por: Witmer, Char M., et al.
Publicado: (2017)

Venous Thromboembolism in Pediatric Vascular Anomalies
por: Nakano, Taizo A., et al.
Publicado: (2017)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism
por: Mahajerin, Arash, et al.
Publicado: (2017)

Venous Thromboembolism Prophylaxis Use by Pediatric Orthopedic Surgeons in Canada for the Pediatric Orthopedic Surgical Population
por: Curwin, Jenna, et al.
Publicado: (2022)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Venous Thromboembolism in Critical Illness and Trauma: Pediatric Perspectives
por: Chima, Ranjit S., et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma
por: Takechi, Tomoki, et al.
Publicado: (2018)

Inherited Thrombophilia in Pediatric Venous Thromboembolic Disease: Why and Who to Test
por: van Ommen, C. Heleen, et al.
Publicado: (2017)

Neonatal Venous Thromboembolism
por: Haley, Kristina M.
Publicado: (2017)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

The Role of Inflammation in Venous Thromboembolism
por: Branchford, Brian R., et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Venous Thromboembolic Complications in Pediatric Gastrointestinal Diseases: Inflammatory Bowel Disease and Intestinal Failure
por: Klomberg, Renz C. W., et al.
Publicado: (2022)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
por: Suri, Ajit, et al.
Publicado: (2020)

Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis
por: Lasagni, Donatella, et al.
Publicado: (2022)

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023)

Venous Thromboembolism in Children with Cancer and Blood Disorders
por: Ko, Richard H., et al.
Publicado: (2017)

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients
por: Schmitz, Michael L., et al.
Publicado: (2020)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017)

National Trends in Venous Thromboembolism in the Adult Craniofacial Trauma Population
por: Lewin, Grant M., et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range
por: Hanley, Michael J., et al.
Publicado: (2017)

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
por: Becattini, Cecilia, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
por: Mian, P., et al.
Publicado: (2019)

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients
por: Ayyoub, Amal, et al.
Publicado: (2016)

Prevention of Hospital-Acquired Venous Thromboembolism in Children: A Review of Published Guidelines
por: Faustino, E. Vincent S., et al.
Publicado: (2017)

Risk Factors, Prophylaxis, and Treatment of Venous Thromboembolism in Congenital Heart Disease Patients
por: Silvey, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9hd69nkrf51055l6hr3ub0guic